The U.S. Veterans Administration measures a substantial reduction in its carbon footprint associated with patient travel by ...

North Carolina is a top state for business. The business un-friendly attitude taken by Andrew Dunn in a News & Observer ...

Merck's stock trades at a low valuation as investors worry about Keytruda's looming patent cliff. The company is looking to a new, subcutaneous formulation, which could help sales remain strong ...

40% of Merck & Co., Inc.'s revenues are driven by cancer med Keytruda, which faces patent expiry by 2028, posing a significant risk to future earnings and share price value. The company is ...

Excluding Greater China, MSD gains rights for developing, manufacturing and commercialising the therapy globally. Credit: Copyright © 2025 Merck & Co., Inc., Rahway ...

Merck & Co. will pay as much as $2 billion for the rights to Jiangsu Hengrui Pharmaceuticals Co.’s experimental heart drug, the US drugmaker’s second recent foray into China for a novel medicine.

Mer­ck has struck a li­cens­ing deal for a car­dio­vas­cu­lar drug with Jiang­su Hen­grui Phar­ma­ceu­ti­cals, the lat­est in a flood of Chi­na deals be­ing made by … ...

Merck (MRK) has signed a licensing agreement for a heart disease drug developed by a Chinese company in a deal worth up to $2 billion, the latest in a series of cross-border deals between Western ...

Merck & Co. is handing over $200 million to China’s Hengrui Pharma for a phase 2-stage lipoprotein(a) (Lp(a)) inhibitor. In return for the ex-China rights to the drug, dubbed HRS-5346, Merck has ...

Merck (NYSE:MRK) has reached a licensing agreement worth nearly $2B with the Chinese drugmaker Jiangsu Hengrui Pharmaceuticals to jointly develop and commercialize an experimental heart disease ...

(Reuters) -Merck has signed a licensing agreement for a heart disease drug with Jiangsu Hengrui Pharmaceuticals worth up to $2 billion, the latest in a series of deals U.S. drugmakers have ...

Under terms of the deal, Merck will gain global rights to develop, manufacture, and commercialize HRS-5346 for cardiovascular disease, excluding Greater China. Merck has entered an exclusive licensing ...